Biodesix Inc (BDSX)vsWaters Corporation (WAT)
BDSX
Biodesix Inc
$28.43
-2.64%
HEALTHCARE · Cap: $284.51M
WAT
Waters Corporation
$423.92
+0.54%
HEALTHCARE · Cap: $41.62B
Smart Verdict
WallStSmart Research — data-driven comparison
Waters Corporation generates 4412% more annual revenue ($4.64B vs $102.94M). WAT leads profitability with a 3.6% profit margin vs -27.0%. WAT earns a higher WallStSmart Score of 45/100 (D+).
BDSX
Avoid29
out of 100
Grade: F
WAT
Hold45
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-8.5%
Fair Value
$9.54
Current Price
$28.43
$18.89 premium
Margin of Safety
-45.9%
Fair Value
$225.66
Current Price
$423.92
$198.26 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 34.2% year-over-year
Revenue surging 113.4% year-over-year
Safe zone — low bankruptcy risk
Reasonable price relative to book value
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Trading at 32.7x book value
ROE of -349.9% — below average capital efficiency
Expensive relative to growth rate
ROE of 1.1% — below average capital efficiency
3.6% margin — thin
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : BDSX
The strongest argument for BDSX centers on Revenue Growth. Revenue growth of 34.2% demonstrates continued momentum.
Bull Case : WAT
The strongest argument for WAT centers on Revenue Growth, Altman Z-Score, Price/Book. Revenue growth of 113.4% demonstrates continued momentum.
Bear Case : BDSX
The primary concerns for BDSX are EPS Growth, Market Cap, Price/Book. Debt-to-equity of 7.85 is elevated, increasing financial risk.
Bear Case : WAT
The primary concerns for WAT are PEG Ratio, Return on Equity, Profit Margin. A P/E of 107.0x leaves little room for execution misses. Thin 3.6% margins leave little buffer for downturns.
Key Dynamics to Monitor
WAT carries more volatility with a beta of 1.19 — expect wider price swings.
WAT is growing revenue faster at 113.4% — sustainability is the question.
WAT generates stronger free cash flow (153M), providing more financial flexibility.
Monitor DIAGNOSTICS & RESEARCH industry trends, competitive dynamics, and regulatory changes.
Bottom Line
WAT scores higher overall (45/100 vs 29/100) and 113.4% revenue growth. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Biodesix Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Biodesix, Inc. operates a data-driven diagnostic solutions company in the United States. The company is headquartered in Boulder, Colorado.
Waters Corporation
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Waters Corporation is a publicly traded Analytical Laboratory instrument and software company headquartered in Milford, Massachusetts.
Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?